Continuous variables were summarized with descriptive statistics, including

- **Objectives:**
  - Treatment permitted
  - ECOG PS ≤2
  - IPSS intermediate-1, or post-ET MF
  - JAK2V617F-positive mouse model

A dose of 300 mg QD was determined to be the recommended Phase 2 dose (RP2D).

- **Safety:**
  - Of evaluable patients, 57% (16/28) achieved a ≥50% reduction in spleen size (Table 5).

Of evaluable patients, 53% (19/36) achieved a ≥50% reduction in spleen size.

- **Pharmacokinetics:**
  - On Day 1, plasma concentration was achieved 1–2 hours post dosing for all dose cohorts.

- **Results:**
  - The most common drug-related hematologic events were thrombocytopenia and anemia, and the frequent drug-related non-hematologic events were diarrhea and nausea (Table 1).

- **Analysis:**
  - The Phase 2 portion of the study is ongoing and only includes patients who have received prior JAK2 inhibitor treatment.

**CONCLUSIONS:**

- Based on tolerability and preliminary efficacy data, the NS-018 300 mg QD dose was recommended for use in the Phase 2 part of the study.

**ACKNOWLEDGMENTS:**

The study was sponsored by NS Pharma, Inc., a subsidiary of Nipponsho Pharma Co., Ltd. The authors received editorial support from Working Communications and Mithra. NS Pharma Inc. also received the support of Bard Strategies, in the creation of the clinical and development of the research and product.

**REFERENCES:**

5. Complete blood count (CBC) changes from baseline week 0 to end of study week 12 (Figure 5).
13. The Phase 1 portion of the study is ongoing and only includes patients who have received prior JAK2 inhibitor treatment.

**DISCLOSURES:**

- No relevant financial interest of any kind was declared or observed in this study.